Forskning ved Københavns Universitet - Københavns Universitet

Forside

Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice. / Aabo, K; Vindeløv, L L; Christensen, I J; Spang-Thomsen, M.

I: International Journal of Cancer, Bind 59, Nr. 3, 1994, s. 394-9.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Aabo, K, Vindeløv, LL, Christensen, IJ & Spang-Thomsen, M 1994, 'Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice', International Journal of Cancer, bind 59, nr. 3, s. 394-9.

APA

Aabo, K., Vindeløv, L. L., Christensen, I. J., & Spang-Thomsen, M. (1994). Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice. International Journal of Cancer, 59(3), 394-9.

Vancouver

Aabo K, Vindeløv LL, Christensen IJ, Spang-Thomsen M. Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice. International Journal of Cancer. 1994;59(3):394-9.

Author

Aabo, K ; Vindeløv, L L ; Christensen, I J ; Spang-Thomsen, M. / Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice. I: International Journal of Cancer. 1994 ; Bind 59, Nr. 3. s. 394-9.

Bibtex

@article{0513020064ba11de8bc9000ea68e967b,
title = "Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice",
abstract = "We investigated the influence of cellular heterogeneity on the response to low-dose BCNU chemotherapy of an artificially mixed human small-cell lung cancer (SCLC) xenograft in nude mice containing a BCNU-sensitive and dominating sub-population and a BCNU-resistant and undetectable (dominated) sub-population. The cell lines differed in DNA content, making them distinguishable by DNA flow cytometry (FCM). After 3 weeks of tumor growth, the mice were stratified according to tumor size and randomized to 2 different low-dose treatments with BCNU or no treatment. After a further 3 to 4 weeks, a high-dose treatment (LD10) was given to both groups of treated tumors. Changes in the relative proportions of and cell lines in the tumors were measured by FCM on fine-needle tumor aspirates. At the time of low-dose treatment, all the tumors were totally dominated by the sensitive cells. A temporary response was seen after low-dose treatment. After the high-dose treatment, a similar short response was seen. In the non-treated group, the sensitive cells continued to dominate. At the time of tumor regrowth after the low-dose treatment, most of the tumors continued to be dominated by the sensitive population. At the time of progression after the response to the high-dose treatment, the resistant cell line was the predominant population. If compared with a single high-dose BCNU treatment, the response of tumors treated with a low dose was superior, indicating that the presence of a dominating and slower growing sub-population influenced the outcome of the treatment.",
author = "K Aabo and Vindel{\o}v, {L L} and Christensen, {I J} and M Spang-Thomsen",
note = "Keywords: Animals; Carcinoma, Small Cell; Carmustine; DNA, Neoplasm; Drug Resistance; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitosis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured",
year = "1994",
language = "English",
volume = "59",
pages = "394--9",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Low-dose chemotherapy delays relapse of a dominated and resistant sub-population in a heterogeneous human SCLC xenograft in nude mice

AU - Aabo, K

AU - Vindeløv, L L

AU - Christensen, I J

AU - Spang-Thomsen, M

N1 - Keywords: Animals; Carcinoma, Small Cell; Carmustine; DNA, Neoplasm; Drug Resistance; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mitosis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Transplantation, Heterologous; Tumor Cells, Cultured

PY - 1994

Y1 - 1994

N2 - We investigated the influence of cellular heterogeneity on the response to low-dose BCNU chemotherapy of an artificially mixed human small-cell lung cancer (SCLC) xenograft in nude mice containing a BCNU-sensitive and dominating sub-population and a BCNU-resistant and undetectable (dominated) sub-population. The cell lines differed in DNA content, making them distinguishable by DNA flow cytometry (FCM). After 3 weeks of tumor growth, the mice were stratified according to tumor size and randomized to 2 different low-dose treatments with BCNU or no treatment. After a further 3 to 4 weeks, a high-dose treatment (LD10) was given to both groups of treated tumors. Changes in the relative proportions of and cell lines in the tumors were measured by FCM on fine-needle tumor aspirates. At the time of low-dose treatment, all the tumors were totally dominated by the sensitive cells. A temporary response was seen after low-dose treatment. After the high-dose treatment, a similar short response was seen. In the non-treated group, the sensitive cells continued to dominate. At the time of tumor regrowth after the low-dose treatment, most of the tumors continued to be dominated by the sensitive population. At the time of progression after the response to the high-dose treatment, the resistant cell line was the predominant population. If compared with a single high-dose BCNU treatment, the response of tumors treated with a low dose was superior, indicating that the presence of a dominating and slower growing sub-population influenced the outcome of the treatment.

AB - We investigated the influence of cellular heterogeneity on the response to low-dose BCNU chemotherapy of an artificially mixed human small-cell lung cancer (SCLC) xenograft in nude mice containing a BCNU-sensitive and dominating sub-population and a BCNU-resistant and undetectable (dominated) sub-population. The cell lines differed in DNA content, making them distinguishable by DNA flow cytometry (FCM). After 3 weeks of tumor growth, the mice were stratified according to tumor size and randomized to 2 different low-dose treatments with BCNU or no treatment. After a further 3 to 4 weeks, a high-dose treatment (LD10) was given to both groups of treated tumors. Changes in the relative proportions of and cell lines in the tumors were measured by FCM on fine-needle tumor aspirates. At the time of low-dose treatment, all the tumors were totally dominated by the sensitive cells. A temporary response was seen after low-dose treatment. After the high-dose treatment, a similar short response was seen. In the non-treated group, the sensitive cells continued to dominate. At the time of tumor regrowth after the low-dose treatment, most of the tumors continued to be dominated by the sensitive population. At the time of progression after the response to the high-dose treatment, the resistant cell line was the predominant population. If compared with a single high-dose BCNU treatment, the response of tumors treated with a low dose was superior, indicating that the presence of a dominating and slower growing sub-population influenced the outcome of the treatment.

M3 - Journal article

C2 - 7927948

VL - 59

SP - 394

EP - 399

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -

ID: 12870280